RNS Number : 8680L
Omega Diagnostics Group PLC
06 January 2023
 

OMEGA DIAGNOSTICS GROUP PLC

("Omega", the "Company" or the "Group")

 

US expansion update

 

Maiden US Laboratory FoodPrint® installation,

Appointment of US importer for FoodPrint® and

First PO from US CLIA certified Lab heralds start of US expansion

 

Omega (AIM: ODX), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, announces that it has now received the maiden purchase order ('PO') for its FoodPrint® system from a CLIA certified ('Clinical Laboratory Improvement Amendments') laboratory in the United States, and has appointed a new US importer for FoodPrint® kits.

 

Using a small finger prick of blood, the FoodPrint® test can quickly identify an individual's unique food sensitivity reactions, allowing the patient to adjust and plan to a new diet and address IgG-mediated food sensitivities. FoodPrint® analyses up to 222 foods for IgG antibodies and is trusted by more than 150 laboratories worldwide, to help fast track a guided elimination diet allowing a more focused and actionable result for practitioners and their patients.

 

The Board expects installation at the laboratory to commence later this month and after a period of validation and gaining necessary approvals, the processing of tests to begin later this quarter. As well as being CLIA certified, the laboratory receiving the system is also College of American Pathologists accredited and specialises in providing functional tests for both consumers and healthcare practitioners.

 

Omega has also secured an importer for FoodPrint® kits into the USA. The importer will import kits for the CLIA laboratory as well as for Omega's own direct channels in future.

 

Although the value of this initial PO is circa £50,000, the US market is a key area of focus for Omega's growth strategy and this installation will be the first in the US market in over seven years, representing the beginning of Omega's planned expansion into the USA.

 

Jag Grewal, CEO of Omega Diagnostics, said: "The US is the single largest market for food sensitivity testing globally, with an ever-increasing demand for personalised medicine, and is a focus area for our growth plans. This installation reflects a key milestone in our expansion plans, the receiving laboratory is ideally placed to commercialise FoodPrint® in the US market as they are already providing a range of other functional tests. The appointment of the US importer will act as a foundation for our expansion into the region.

 

"Once the system has been commissioned, we plan to collaborate closely with our laboratory partner to ensure FoodPrint® is promoted effectively through their existing healthcare practitioner and direct to consumer channels."

 

 

Contacts: 

Omega Diagnostics Group PLC 

www.omegadx.com

Jag Grewal, Chief Executive Officer 

via Walbrook PR

Chris Lea, Chief Financial Officer






finnCap Ltd  

Tel: 020 7220 0500

Geoff Nash/Edward Whiley/George Dollemore (Corporate Finance)


Alice Lane/Charlotte Sutcliffe (ECM)






Walbrook PR Limited

Tel: 020 7933 8780 or omega@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Applegarth

Mob: 07584 391 303

Sam Allen

Mob: 07502 558 258

 

About Omega Diagnostics Group PLC

Omega (AIM: ODX) is a specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition.

www.omegadx.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDBAMLTMTTMBAJ